Purpose: To prospectively evaluate the ability of diffusion-weighted (DW) magnetic resonance (MR) imaging to be used to determine the T stage of bladder cancer and to measure the correlation between the apparent diffusion coefficient (ADC) and histologic grade.
Materials And Methods: This study was approved by the local institutional review board. All patients gave written informed consent. Forty patients with a total of 52 bladder tumors underwent MR imaging that included DW imaging. Histologic grade was determined for all tumors. Two radiologists interpreted four image sets (ie, T2-weighted images alone, T2-weighted plus DW images, T2-weighted plus dynamic contrast agent-enhanced images, all three image types together). Conventional criteria were used for interpreting T2-weighted and contrast-enhanced images. For DW images, new staging criterion developed on the basis of the hypothesis that tumors, submucosal tissue, and muscles show high, low, and intermediate signal intensity, respectively, was used. The McNemar test was used to examine differences in accuracy, sensitivity, and specificity. Differences in the performance were analyzed by comparing the areas under the receiver operating characteristic curves (A(z) values). To compare ADCs between three histologic grades, analysis of variance was used.
Results: The overall accuracy of T stage diagnosis was 67% for T2-weighted images alone, 88% for T2-weighted plus DW images, 79% for T2-weighted plus contrast-enhanced images, and 92% for all three image types together. The overall accuracy, specificity, and A(z) for diagnosing T2 or higher stages were significantly improved by adding DW images (P < .01). The mean ADC of G3 tumors was significantly lower than that of G1 and G2 tumors (P < .01).
Conclusion: DW images provided useful information for evaluating the T stage of bladder cancer, particularly in differentiating T1 or lower tumors from T2 or higher tumors. The ADC may in part predict the histologic grade of bladder cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1148/radiol.2511080873 | DOI Listing |
BJU Int
January 2025
EADV Task Force on Tattoos and Body Art, Lugano, Switzerland.
Tech Innov Patient Support Radiat Oncol
March 2025
Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Tokushima 770-8503, Japan.
Purpose: This study aims to compare treatment plans created using RapidPlan and PlanIQ for twelve patients with prostate cancer, focusing on dose uniformity, dose reduction to organs at risk (OARs), plan complexity, and dose verification accuracy. The goal is to identify the tool that demonstrates superior performance in achieving uniform target dose distribution and reducing OAR dose, while ensuring accurate dose verification.
Methods: Dose uniformity in the planning target volume, excluding the rectum, and dose reduction in the OARs (the rectum and bladder) were assessed.
J Surg Oncol
January 2025
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background And Objectives: IO has transformed cancer management, but its adoption in advanced cancer patients varies by tumor type. With more Stage IV patients undergoing surgery, understanding site-specific outcomes in these challenging patients is essential. We aimed to evaluate IO use and survival trends for Stage IV cancer patients across high-incidence cancers in the US.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China; Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, China. Electronic address:
Chemotherapy remains a cornerstone in the treatment of bladder cancer (BLCA); however, the development of chemoresistance substantially limits its efficacy and significantly affects patient survival. Thus, elucidating the molecular mechanisms underlying BLCA chemoresistance is critical to improving patient outcomes. Our study identified MCM6 as an oncogene that facilitates BLCA proliferation and invasion and is linked to cisplatin resistance.
View Article and Find Full Text PDFAm J Clin Pathol
January 2025
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Objectives: Immune checkpoint inhibitors have revolutionized treatment of platinum-refractory advanced bladder cancer, offering hope where options are limited. Response varies, however, influenced by factors such as the tumor's immune microenvironment and prior therapy. Muscle-invasive bladder cancer (MIBC) is stratified into molecular subtypes, with distinct clinicopathologic features affecting prognosis and treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!